Fmoc-Asp(OtBu)-OH-13C4,15N

Modify Date: 2024-08-06 18:39:31

Fmoc-Asp(OtBu)-OH-13C4,15N Structure
Fmoc-Asp(OtBu)-OH-13C4,15N structure
Common Name Fmoc-Asp(OtBu)-OH-13C4,15N
CAS Number 1160760-08-6 Molecular Weight 416.41
Density N/A Boiling Point N/A
Molecular Formula C1913C4H2515NO6 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Fmoc-Asp(OtBu)-OH-13C4,15N


Fmoc-Asp(OtBu)-OH-13C4,15N is the 13C and 15N labeled Fmoc-Asp(OtBu)-OH[1]. Fmoc-Asp(OtBu)-OH (4-tert-Butyl N-(fluoren-9-ylmethoxycarbonyl)-L-aspartate) is a aspartate derivative containing amine protecting group Fmoc. Fmoc-Asp(OtBu)-OH can be used for peptide synthesis[2].

 Names

Name Fmoc-Asp(OtBu)-OH-13C4,15N

 Fmoc-Asp(OtBu)-OH-13C4,15N Biological Activity

Description Fmoc-Asp(OtBu)-OH-13C4,15N is the 13C and 15N labeled Fmoc-Asp(OtBu)-OH[1]. Fmoc-Asp(OtBu)-OH (4-tert-Butyl N-(fluoren-9-ylmethoxycarbonyl)-L-aspartate) is a aspartate derivative containing amine protecting group Fmoc. Fmoc-Asp(OtBu)-OH can be used for peptide synthesis[2].
Related Catalog
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  

[2]. Esquivel J B, et al. Chiral HPLC separation of protected amino acids. Journal of liquid chromatography & related technologies, 1998, 21(6): 777-791.

 Chemical & Physical Properties

Molecular Formula C1913C4H2515NO6
Molecular Weight 416.41